Literature DB >> 21978383

Minimally invasive intra-arterial regional therapy for metastatic melanoma: isolated limb infusion and percutaneous hepatic perfusion.

Dale Han1, Georgia M Beasley, Douglas S Tyler, Jonathan S Zager.   

Abstract

INTRODUCTION: In-transit melanoma or melanoma presenting as unresectable liver metastases are clinical situations with limited therapeutic options. Regional intra-arterial therapies provide efficacious treatment alternatives for these patients. Through surgical techniques of vascular isolation, regional therapies deliver high-dose chemotherapy to tumor cells while minimizing systemic exposure. However, percutaneous techniques such as isolated limb infusion (ILI) and percutaneous hepatic perfusion (PHP) have been developed, which provide a minimally invasive means of obtaining vascular isolation of target organs. AREAS COVERED: Areas covered in this review include the techniques of ILI and PHP, the chemotherapeutic agents utilized during these regional therapies and the clinical responses seen after ILI and PHP. The pharmacokinetics of regional chemotherapy utilized during ILI and PHP is also reviewed with an additional focus on novel ways to optimize drug delivery to improve response rates and attempts to define the potential systemic manifestations of regional therapeutics. EXPERT OPINION: Unresectable hepatic and limb in-transit metastases from melanoma are very difficult to treat. Systemic chemotherapy has largely been ineffective. Both the minimally invasive, percutaneous techniques of ILI and PHP are excellent methods used to deliver extremely high-dose chemotherapy regionally to patients harboring metastatic melanoma confined to an extremity or liver, respectively. Studies, from prospectively maintained databases as well as Phase II and III trials, have shown the great efficacy of these techniques.

Entities:  

Mesh:

Year:  2011        PMID: 21978383      PMCID: PMC4630979          DOI: 10.1517/17425255.2011.609555

Source DB:  PubMed          Journal:  Expert Opin Drug Metab Toxicol        ISSN: 1742-5255            Impact factor:   4.481


  80 in total

Review 1.  Locoregional management of hepatic metastasis from primary uveal melanoma.

Authors:  Takami Sato
Journal:  Semin Oncol       Date:  2010-04       Impact factor: 4.929

2.  Marked variability of melphalan plasma drug levels during regional hyperthermic isolated limb perfusion.

Authors:  Tsung-Yen Cheng; Elizabeth Grubbs; Omar Abdul-Wahab; Szu-Yun Leu; Chen-Fang Hung; William Petros; Thomas Aloia; Randy Fedrau; Scott Pruitt; Michael Colvin; Henry Friedman; Douglas Tyler
Journal:  Am J Surg       Date:  2003-11       Impact factor: 2.565

3.  Very long-term prognosis of patients with malignant uveal melanoma.

Authors:  Emma Kujala; Teemu Mäkitie; Tero Kivelä
Journal:  Invest Ophthalmol Vis Sci       Date:  2003-11       Impact factor: 4.799

4.  Prognostic factors for tumor response and limb recurrence-free interval in patients with advanced melanoma of the limbs treated with regional isolated perfusion with melphalan.

Authors:  J M Klaase; B B Kroon; A N van Geel; A M Eggermont; H R Franklin; A A Hart
Journal:  Surgery       Date:  1994-01       Impact factor: 3.982

5.  Modulation of resistance to regional chemotherapy in the extremity melanoma model.

Authors:  Elizabeth G Grubbs; Tomio Ueno; Omar Abdel-Wahab; Tsung-Yen Cheng; Scott K Pruitt; O Michael Colvin; Henry S Friedman; Douglas S Tyler
Journal:  Surgery       Date:  2004-08       Impact factor: 3.982

6.  Long-term results of hyperthermic, isolated limb perfusion for melanoma: a reflection of tumor biology.

Authors:  Amira Sanki; Peter C A Kam; John F Thompson
Journal:  Ann Surg       Date:  2007-04       Impact factor: 12.969

7.  Percutaneous hepatic perfusion in patients with metastatic liver cancer: anesthetic, hemodynamic, and metabolic considerations.

Authors:  Ning Miao; James F Pingpank; H Richard Alexander; Seth M Steinberg; Tatiana Beresneva; Zenaide M N Quezado
Journal:  Ann Surg Oncol       Date:  2008-01-08       Impact factor: 5.344

8.  A highly conserved vascular permeability factor secreted by a variety of human and rodent tumor cell lines.

Authors:  D R Senger; C A Perruzzi; J Feder; H F Dvorak
Journal:  Cancer Res       Date:  1986-11       Impact factor: 12.701

Review 9.  Angiogenesis in melanoma.

Authors:  Ganapati H Mahabeleshwar; Tatiana V Byzova
Journal:  Semin Oncol       Date:  2007-12       Impact factor: 4.929

10.  BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis.

Authors:  Scott M Wilhelm; Christopher Carter; Liya Tang; Dean Wilkie; Angela McNabola; Hong Rong; Charles Chen; Xiaomei Zhang; Patrick Vincent; Mark McHugh; Yichen Cao; Jaleel Shujath; Susan Gawlak; Deepa Eveleigh; Bruce Rowley; Li Liu; Lila Adnane; Mark Lynch; Daniel Auclair; Ian Taylor; Rich Gedrich; Andrei Voznesensky; Bernd Riedl; Leonard E Post; Gideon Bollag; Pamela A Trail
Journal:  Cancer Res       Date:  2004-10-01       Impact factor: 13.312

View more
  3 in total

1.  Hepatic Progression-free and Overall Survival After Regional Therapy to the Liver for Metastatic Melanoma.

Authors:  Andrea M Abbott; Matthew P Doepker; Youngchul Kim; Matthew C Perez; Cassandra Gandle; Kerry L Thomas; Junsung Choi; Ravi Shridhar; Jonathan S Zager
Journal:  Am J Clin Oncol       Date:  2018-08       Impact factor: 2.339

2.  Results of a Randomized Controlled Multicenter Phase III Trial of Percutaneous Hepatic Perfusion Compared with Best Available Care for Patients with Melanoma Liver Metastases.

Authors:  Marybeth S Hughes; Jonathan Zager; Mark Faries; H Richard Alexander; Richard E Royal; Bradford Wood; Junsung Choi; Kevin McCluskey; Eric Whitman; Sanjiv Agarwala; Gary Siskin; Charles Nutting; Mary Ann Toomey; Carole Webb; Tatiana Beresnev; James F Pingpank
Journal:  Ann Surg Oncol       Date:  2015-11-23       Impact factor: 5.344

3.  Chemosaturation with percutaneous hepatic perfusion for unresectable metastatic melanoma or sarcoma to the liver: a single institution experience.

Authors:  Meghan R Forster; Omar M Rashid; Matthew C Perez; Junsung Choi; Tariq Chaudhry; Jonathan S Zager
Journal:  J Surg Oncol       Date:  2013-11-19       Impact factor: 3.454

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.